SCHEMBL4722672

SCHEMBL4722672

Cc1c(C(=O)O)n(-c2ccc(Cl)cc2)c2nc[nH]c(=O)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
NPC1 O15118 1/20 0.41
MAPT P10636 5/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 1/20 0.40
NOTUM Q6P988 1/20 0.39
KMT2A Q03164 1/20 0.38
CCNE2 O96020 1/20 0.37
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
BLM P54132 1/20 0.37
SRC P12931 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717730 0.89 MAPT (0.48) BCAT2MAPTLMNAHTTKMT2A
SCHEMBL4721414 0.87 MAPT (0.46) BCAT2NPC1MAPTLMNAHTT
SCHEMBL290505 0.85 KDM4E (0.48) NPC1MAPTLMNAHTTKMT2A
SCHEMBL4542766 0.81 NOTUM (0.41) BCAT2MAPTLMNAHTTNOTUM
SCHEMBL5462039 0.80 MAPT (0.49) MAPTLMNAHTTKMT2ASRC
SCHEMBL4722651 0.77 PDE4A (0.42) BCAT2MAPTLMNAHTTNOTUM
SCHEMBL290869 0.77 HPGD (0.48) BCAT2MAPTLMNAHTTKMT2A
SCHEMBL4718179 0.77 NPC1 (0.41) CA12CA1CA2CA9NPC1
SCHEMBL4720274 0.76 BCAT2 (0.43) BCAT2NPC1MAPTLMNAHTT
SCHEMBL4720241 0.76 MAPT (0.46) BCAT2MAPTLMNAHTTNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458722-B1 PYRROLOPYRIMIDINES AS PHOSPHODIESTERASE VII INHIBITORS MERCK PATENT GMBH (DE) 2008-10-15 EP claimed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 CN disclosed